ZA200306541B - Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin. - Google Patents

Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin.

Info

Publication number
ZA200306541B
ZA200306541B ZA200306541A ZA200306541A ZA200306541B ZA 200306541 B ZA200306541 B ZA 200306541B ZA 200306541 A ZA200306541 A ZA 200306541A ZA 200306541 A ZA200306541 A ZA 200306541A ZA 200306541 B ZA200306541 B ZA 200306541B
Authority
ZA
South Africa
Prior art keywords
tegafur
carboplatin
paclitaxel
uracil
administration
Prior art date
Application number
ZA200306541A
Other languages
English (en)
Inventor
Jafferhusen A Ajani
Terry S Dugan
Steven E Benner
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA200306541B publication Critical patent/ZA200306541B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200306541A 2001-03-06 2003-08-21 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin. ZA200306541B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06

Publications (1)

Publication Number Publication Date
ZA200306541B true ZA200306541B (en) 2004-11-22

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200306541A ZA200306541B (en) 2001-03-06 2003-08-21 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin.

Country Status (20)

Country Link
US (1) US6770653B2 (cg-RX-API-DMAC7.html)
EP (1) EP1368034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506294A (cg-RX-API-DMAC7.html)
KR (1) KR20030081496A (cg-RX-API-DMAC7.html)
BR (1) BR0207443A (cg-RX-API-DMAC7.html)
CA (1) CA2439676A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20032266A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300429A (cg-RX-API-DMAC7.html)
HR (1) HRP20030801A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0303466A3 (cg-RX-API-DMAC7.html)
IL (1) IL157357A0 (cg-RX-API-DMAC7.html)
IS (1) IS6925A (cg-RX-API-DMAC7.html)
MX (1) MXPA03007989A (cg-RX-API-DMAC7.html)
NO (1) NO20033910L (cg-RX-API-DMAC7.html)
PL (1) PL363967A1 (cg-RX-API-DMAC7.html)
RU (1) RU2284184C2 (cg-RX-API-DMAC7.html)
SK (1) SK10602003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002076459A1 (cg-RX-API-DMAC7.html)
YU (1) YU69903A (cg-RX-API-DMAC7.html)
ZA (1) ZA200306541B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素-743在制备用于治疗肿瘤的药剂中的应用
JP4610481B2 (ja) 2003-03-14 2011-01-12 大鵬薬品工業株式会社 抗腫瘍効果増強剤及び抗腫瘍剤
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー, ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI2301531T1 (sl) 2005-02-18 2018-11-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Et−743治療のための予後分子マーカー
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
CA2983411C (en) * 2015-04-22 2023-02-21 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
JP7008025B2 (ja) 2016-08-31 2022-01-25 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
AU2018404329B2 (en) 2018-01-29 2021-09-09 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Also Published As

Publication number Publication date
HUP0303466A2 (hu) 2004-01-28
MXPA03007989A (es) 2003-12-04
KR20030081496A (ko) 2003-10-17
CA2439676A1 (en) 2002-10-03
US6770653B2 (en) 2004-08-03
RU2003129527A (ru) 2005-03-10
WO2002076459A1 (en) 2002-10-03
RU2284184C2 (ru) 2006-09-27
NO20033910D0 (no) 2003-09-04
CZ20032266A3 (cs) 2004-02-18
HRP20030801A2 (en) 2004-08-31
SK10602003A3 (en) 2004-10-05
NO20033910L (no) 2003-10-23
BR0207443A (pt) 2004-04-06
IL157357A0 (en) 2004-02-19
EE200300429A (et) 2003-12-15
YU69903A (sh) 2006-08-17
US20020173482A1 (en) 2002-11-21
HUP0303466A3 (en) 2005-02-28
EP1368034A1 (en) 2003-12-10
IS6925A (is) 2003-08-22
PL363967A1 (en) 2004-11-29
JP2005506294A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
ZA200306541B (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin.
WO2003080582A3 (de) Fredericamycin-derivate
IL162348A (en) Oxaliplatin formulations, method for stabilizing same and use thereof for preparing medicaments for treating cancer
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
HK1047236A1 (zh) 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
YU91002A (sh) Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
HUP0402588A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
MXPA03005018A (es) Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos, y su uso.
MXPA03005019A (es) Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso.
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
EP1698329A4 (en) PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2002067893A3 (en) Pharmaceutical formulation comprising bicalutamide
PL378369A1 (pl) Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
MXPA03001484A (es) Quinazolinas, medicamentos que contienen estos compuestos, y son efectivos como inhbidores de tirosina quinasa, su utilizacion y metodos para su produccion.
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
AU2001240001A1 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
MXPA03009681A (es) METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA.
ZA200302159B (en) New compounds derived from quinazoline, a process for their preparation and pharmaceutical compositions containing them.
HK1060518A (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
HK1060256A (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
TW200626588A (en) (Arylamidoaryl)cyanoguanidine compounds
MXPA03008588A (es) Nuevos derivados de pirimidin-2,4,6-triona, procedimiento para su produccion y agentes farmaceuticos que contienen estos compuestos.